Evidence map›Paper›PMID 37498394›Full record

ArticleMedical oncology (Northwood, London, England)2023

Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma.

Wenbin Liu, Zhiguo Xie, Kefeng Shen, Lizhu Jiang, Chongyan Liu, Yongsheng Ge, Jihai Yu, Weidong Jia, Jinliang Ma, Hao Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wenbin Liu *Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Zhiguo Xie *Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Kefeng Shen *Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Lizhu Jiang *Division of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Chongyan LiuDivision of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Yongsheng GeDivision of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Jihai YuDivision of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Weidong JiaDivision of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Jinliang MaDivision of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China.
Hao ChenDivision of Life Sciences and Medicine, Department of Hepatic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China, HeFei, 230001, Anhui, China. ch2446@ustc.edu.cn.ORCID http://orcid.org/0000-0001-9706-4729
University of Science and Technology of China · CN

Funding

Anhui Provincial Key Research and Development Plan 1804h08020281Anhui Provincial Key Research and Development Plan 201904a07020096Natural Science Foundation of Anhui Province 2108085MH285
6 · The paper itself

Abstract

To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune and targeted therapy in unresectable hepatocellular carcinoma (HCC). Prospective analysis of 23 patients with intermediate or advanced primary HCC treated at the Department of Hepatic Surgery, The First Affiliated Hospital of the University of Science and Technology of China from July 2019, including 11 cases treated with TACE alone and 12 cases treated with TACE combined with targeted therapy. The basal indexes of patients in the two groups were compared, and the response during treatment was observed; regular follow-up was performed to assess the efficacy of tumor treatment. Compared with TACE treatment alone, the objective response rate (ORR) was significantly higher in the TACE combined with targeted treatment group (50.0% vs 36.4%), with a higher success rate of surgical conversion (33.3% vs 18.2%) and a significantly longer progression-free survival (PFS) (20.5 ± 2.9 months vs 11.6 ± 2.9 months). Multifactorial regression analysis identified tumor vascular invasion as an independent prognostic factor affecting HCC. No patient experienced catheter retention-related complications during treatment, and there were no intolerable adverse effects. TACE combined with targeted treatment for intermediate to advanced unresectable HCC was effective, with good tumor responsiveness, high surgical conversion rate, and safe and controllable adverse reactions during treatment.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsCombined Modality TherapyHumansImmunotherapyTreatment OutcomeHepatocellular carcinomaImmunotherapyTargeted therapyTransarterial chemoembolizationTranslational therapy

Identifiers

PMID37498394
OpenAlexW4385295541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.